Source generic drugs, APIs & biosimilars from FDA-compliant Egyptian manufacturers. KEMET connects U.S. pharma buyers with cGMP-certified manufacturers. $721B market.
The U.S. pharmaceutical market's insatiable appetite for cost-effective generics, APIs, and biosimilars creates a historic entry point for Egyptian manufacturers. Egypt's established chemical manufacturing base, skilled workforce, and competitive cost structure make it an ideal contract manufacturing destination.
Growth drivers align perfectly with Egypt's strengths: aging population demand for generics, chronic disease management, and the global push for supply chain diversification.
Egypt's opportunity encompasses the full pharmaceutical value chain — from raw API synthesis to finished-dose formulation. KEMET guides manufacturers through every step, from FDA Drug Establishment Registration to cGMP compliance and U.S. buyer matchmaking.
Generic drug formulation, active pharmaceutical ingredients (APIs), contract manufacturing organizations (CMOs), biologics development, and OTC medication production.
KEMET guides Egyptian pharmaceutical manufacturers from FDA registration through buyer matching.
KEMET's verified factory network and end-to-end managed trade make Egyptian sourcing de-risked and direct.